Unjha Formulations shareholders approve FY26 results, appoint Krutiben Patel as MD

1 min read     Updated on 14 Aug 2026, 12:20 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Unjha Formulations Limited concluded its 32nd AGM on August 14, 2026, with shareholders approving the FY26 audited financials. Key governance changes included the reappointment of Chairperson Jashodaben S. Patel and the new appointment of Krutiben M. Patel as Managing Director for three years. Related party transactions for FY27 were also approved.

powered bylight_fuzz_icon
48235838

*this image is generated using AI for illustrative purposes only.

Unjha Formulations Limited ( Unjha Formulations ) shareholders approved the company’s audited financial statements for the fiscal year ended March 31, 2026, during its 32nd Annual General Meeting (AGM) held on August 14, 2026. The meeting, convened at the company’s registered office in Sidhpur, Gujarat, also resulted in the appointment of Krutiben M. Patel as Managing Director for a three-year term.

The AGM was declared open by Company Secretary Khushboo N. Patel after confirming the presence of quorum. All directors attended the proceedings. Ajay Parikh & Associates served as the secretarial auditors and scrutinizers for the votes cast via remote e-voting and during the physical meeting.

Key Resolutions Passed

The shareholders transacted the following businesses through remote e-voting and e-voting at the venue, in compliance with the Companies Act, 2013 and SEBI regulations:

Ordinary Resolutions:

  • Adoption of the audited financial statements for the year ended March 31, 2026.
  • Appointment of Jashodaben S. Patel (DIN 05201715) as a director in place of her retirement by rotation.

Special Resolutions:

  • Approval of related party transactions for the fiscal year 2026-27.
  • Appointment of Krutiben M. Patel as Managing Director for a term of three years.

Management Commentary

Jashodaben S. Patel, Chairperson, delivered the statement on the affairs of the company. Krutiben Patel, Managing Director, addressed questions raised by members regarding the resolutions. The voting process continued for an additional 15 minutes on the CDSL platform to allow remaining members to cast their votes. The meeting concluded at 11:40 am.

Detailed voting results, as required under Regulation 44(3) of the SEBI Listing Regulations, were submitted separately to the exchanges.

Historical Stock Returns for Unjha Formulations

1 Day5 Days1 Month6 Months1 Year5 Years
+3.70%+17.40%+14.99%+20.22%+13.54%+167.94%

How is the appointment of Krutiben M. Patel as Managing Director expected to influence Unjha Formulations' strategic growth and operational efficiency over the next three years?

What specific growth initiatives or capital expenditure plans are implied by the approval of related party transactions for the fiscal year 2026-27?

Given the adoption of financials for FY 2026, what are the management's projected revenue and margin targets for the upcoming fiscal year amidst current pharmaceutical market dynamics?

Unjha Formulations Q1 Results: Net profit rises to ₹15.69 lakh

2 min read     Updated on 03 Aug 2026, 03:16 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Unjha Formulations Limited posted a net profit of ₹15.69 lakh in Q1FY27, reversing a loss of ₹74.28 lakh from Q4FY26. Revenue remained stable at ₹330.75 lakh, while total expenses fell to ₹314.98 lakh due to reduced employee benefits and favorable inventory adjustments. The results were approved by the Board on August 3, 2026.

powered bylight_fuzz_icon
47295997

*this image is generated using AI for illustrative purposes only.

Unjha Formulations returned to profitability in Q1FY27, reporting a net profit of ₹15.69 lakh for the quarter ended June 30, 2026. This stands in contrast to a net loss of ₹74.28 lakh reported in the same quarter of the previous fiscal year. The company’s Board of Directors approved the unaudited financial results on August 3, 2026, following a review by its statutory auditors.

The turnaround was driven by improved operational efficiency rather than top-line growth. Total income from operations remained relatively flat at ₹330.67 lakh compared to ₹332.83 lakh in Q4FY26 and ₹363.40 lakh in Q1FY26. However, total expenses decreased significantly to ₹314.98 lakh from ₹382.21 lakh in the preceding quarter and ₹324.41 lakh in the same quarter last year.

Financial Performance Overview

The company’s net sales/income from operations were recorded at ₹330.75 lakh for Q1FY26, a slight increase from ₹327.81 lakh in Q4FY26 but lower than the ₹361.41 lakh reported in Q1FY26. Other operating income declined to -₹0.08 lakh from ₹5.02 lakh in the previous quarter.

Metric Q1FY27 (₹ Lakh) Q4FY26 (₹ Lakh) Q1FY26 (₹ Lakh)
Net Sales/Income 330.75 327.81 361.41
Total Expenses 314.98 382.21 324.41
Profit Before Tax 15.69 -49.38 38.99
Net Profit 15.69 -74.28 38.99

Cost of materials consumed rose to ₹319.66 lakh from ₹313.55 lakh in Q4FY26. However, this was offset by a significant reduction in employee benefits expenses, which fell to ₹20.90 lakh from ₹33.93 lakh in the previous quarter. Other expenses also decreased to ₹27.20 lakh from ₹26.35 lakh.

What the Numbers Show

The primary driver of the quarterly profit was a sharp reduction in operating costs despite stable revenue levels. While material costs increased slightly, the substantial drop in employee benefits expenses contributed to a healthier bottom line. The company also benefited from changes in inventories, which showed a positive adjustment of -₹56.63 lakh, compared to an expense of ₹3.70 lakh in Q4FY26. This inventory management efficiency played a key role in narrowing the gap between income and expenses.

Auditor Review and Compliance

The financial results were reviewed by M/s Jain & Golechha, Chartered Accountants, in accordance with Standard on Review Engagement (SRE) 2410. The auditor issued a limited review report stating that nothing came to their attention to suggest the financial statements contained material misstatements. The results comply with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Krutiben M. Patel, Managing Director, and Ganpat Prajapati, CFO, signed off on the results. The company disclosed no pending investor complaints at the beginning or end of the quarter. With only one business segment, all figures represent operations within this single segment.

Historical Stock Returns for Unjha Formulations

1 Day5 Days1 Month6 Months1 Year5 Years
+3.70%+17.40%+14.99%+20.22%+13.54%+167.94%

Can the reduction in employee benefits expenses be sustained in future quarters without impacting operational capacity or employee morale?

How does management plan to reverse the declining trend in net sales, which has decreased from ₹361.41 lakh in Q1FY26 to ₹330.75 lakh in Q1FY27?

What specific strategies is Unjha Formulations implementing to manage rising material costs, which increased to ₹319.66 lakh despite stable revenue?

More News on Unjha Formulations

1 Year Returns:+13.54%